Roche Holding AG (OTCMKTS:RHHBY) Stock Holdings Trimmed by Meritage Portfolio Management

Meritage Portfolio Management reduced its stake in Roche Holding AG (OTCMKTS:RHHBY) by 3.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 162,980 shares of the company’s stock after selling 6,086 shares during the period. Meritage Portfolio Management’s holdings in Roche were worth $5,685,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. GAMMA Investing LLC grew its holdings in Roche by 57.7% during the third quarter. GAMMA Investing LLC now owns 7,944 shares of the company’s stock worth $317,000 after acquiring an additional 2,906 shares during the period. Diversified Trust Co boosted its stake in shares of Roche by 6.4% during the 3rd quarter. Diversified Trust Co now owns 59,742 shares of the company’s stock worth $2,396,000 after acquiring an additional 3,613 shares in the last quarter. AlphaMark Advisors LLC acquired a new position in shares of Roche in the 3rd quarter worth $149,000. Kornitzer Capital Management Inc. KS raised its position in shares of Roche by 1.3% during the third quarter. Kornitzer Capital Management Inc. KS now owns 136,923 shares of the company’s stock worth $5,490,000 after purchasing an additional 1,798 shares during the period. Finally, Verity Asset Management Inc. purchased a new stake in shares of Roche during the third quarter valued at $253,000.

Roche Price Performance

Shares of OTCMKTS:RHHBY opened at $39.62 on Wednesday. Roche Holding AG has a 1 year low of $29.20 and a 1 year high of $42.43. The firm has a fifty day moving average price of $36.38 and a 200 day moving average price of $38.28. The company has a current ratio of 1.26, a quick ratio of 0.97 and a debt-to-equity ratio of 0.86.

Analysts Set New Price Targets

Separately, Sanford C. Bernstein upgraded shares of Roche to a “strong-buy” rating in a research report on Thursday, January 30th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating, one has issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold”.

Roche Profile

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.